Related Experiment Videos
Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis
D Keim1, C Ragsdale, K Heidelberger
1Department of Pediatrics, University of Michigan Hospitals, Ann Arbor.
Abstract:
Methotrexate (MTX) is currently under study for use in juvenile rheumatoid arthritis. One complication of MTX is hepatotoxicity. Although liver function tests may be abnormal with its use, in this setting they do not correlate well with the development of hepatic fibrosis. Periodic liver biopsy is required to monitor for the hepatotoxic changes secondary to MTX. We describe and discuss the case of a 17-year-old woman who developed evidence of hepatic fibrosis after 3 years of MTX therapy.
Insights
Methotrexate (MTX) can cause liver damage in juvenile rheumatoid arthritis patients. Liver biopsies are crucial for detecting MTX-induced hepatic fibrosis, as standard liver function tests are unreliable indicators.
Area of Science:
- Rheumatology
- Hepatology
- Pediatric Rheumatology
Background:
- Methotrexate (MTX) is a common treatment for juvenile rheumatoid arthritis (JRA).
- Hepatotoxicity is a known complication of MTX therapy.
- Standard liver function tests (LFTs) may not accurately reflect MTX-induced liver damage, specifically hepatic fibrosis.
Observation:
- A case study of a 17-year-old female patient with JRA treated with MTX is presented.
- The patient developed evidence of hepatic fibrosis after 3 years of MTX therapy.
Findings:
- In JRA patients treated with MTX, abnormal LFTs do not reliably correlate with the development of hepatic fibrosis.
- Periodic liver biopsy is essential for monitoring MTX-related hepatotoxicity and detecting early signs of fibrosis.
Implications:
- This case highlights the critical need for vigilant monitoring of MTX therapy in pediatric patients with JRA.
- Liver biopsy remains the gold standard for assessing MTX-induced hepatic fibrosis, underscoring limitations of non-invasive markers.
- Clinical practice should emphasize regular liver biopsy in JRA patients on long-term MTX to prevent severe liver complications.